

Awards...



ASTELLAS NAMED BEST WORKPLACE FOR LGBTQ

For the fourth consecutive year, Astellas has achieved a perfect score on the Human Rights Campaign Foundation's annual Corporate Equality Index. The 2018 CEI evaluates LGBTQ-related policies and practices, including non-discrimination workplace protections, domestic partner benefits, transgender-inclusive healthcare benefits, competency programs, and public engagement with the LGBTQ community.

BIOGEN AND IONIS WIN PRESTIGIOUS PRIX GALIEN AWARD


Biogen and Ionis have been awarded the 2017 Prix Galien USA Award for Best Biotechnology Product for Spinraza. The Prix Galien USA Award recognizes extraordinary achievement in scientific innovation that improves the state of human health. Spinraza is the first and only FDA-approved treatment for spinal muscular atrophy.

ALKERMES AND FLEXIO NAMED BEST BOSTON EMPLOYERS

Alkermes and Flexio Therapeutics have been named The Boston Globe's Top Places to Work. The Top Places to Work recognition applauds the most admired workplaces in Massachusetts based on anonymous employee feedback collected through a survey.

ERT RECOGNIZED FOR EXCELLENCE IN PATIENT CENTRICITY

ERT has been recognized with a CPhI Pharma Award for Excellence in Patient Centricity. The award is for TARGET My Hives, a patient community app from ERT that enables access to an online network of resources and health professionals for patients with hives.



Merck Expands DONATION PROGRAM



Merck expands the Mectizan Donation Program to reach people with elephantiasis, a parasitic disease transmitted to humans through the bites of mosquitoes.

Merck has expanded the Mectizan Donation Program (MDP) to reach an additional 100 million people a year through 2025 as part of its global effort to eliminate lymphatic filariasis (LF). Through the MDP,

established by Merck in 1987, the company donates Mectizan for onchocerciasis (river blindness) in Latin America, Africa, Yemen and for LF in African countries where it co-exists with river blindness.



Workers' Comp DRUG SPEND CONTINUES TO DROP

CompPharma's 14th Annual Survey of Prescription Drug Management in Workers' Compensation showed an average 11% reduction in payers' pharmacy spend, driven by a 13.3% reduction in opioid cost. The survey analyzed the 2016 pharmacy cost data of 23 workers' compensation insurance carriers, third-party administrators, self-insured employers, and state funds. In contrast, across all payer types, pain medication use declined by 1%, according to Quintiles IMS (now IQVIA).


PhRMA Elects NEW OFFICERS

The Pharmaceutical Research and Manufacturers of America (PhRMA) has elected new officers to its board of directors. Robert Bradway, chairman and CEO of Amgen, was elected chairman-elect. Olivier Brandicourt, CEO of Sanofi, has been named chairman-elect and PharmaVOICE 100 honoree Jim Robinson, president, Astellas Americas, assumes the role of board treasurer effective Feb. 7, 2018.

Mr. Bradway formerly held the position of board treasurer and will succeed Joaquin Duato, executive VP and worldwide chairman, pharmaceuticals, Johnson & Johnson, as PhRMA board chairman, in February 2018.



Robert Bradway



Olivier Brandicourt

(c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact mwals@pharmavoices.com

TRUSTED PERFORMANCE

(c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact mwals@pharmavoic.com

For a complimentary consultation,
call us at 1-866-616-4777.

impact@touchpointsolutions.com

TouchpointSolutions.com

THE HEALTHCARE COMMERCIALIZATION COMPANY

For leaders of biopharmaceutical and life sciences companies seeking a broadly experienced partner offering end-to-end commercial services, Publicis Health is a trusted source for the transformational insight, creative strategy, and expert resources needed to effectively navigate a rapidly changing, highly complex commercial environment.



Touchpoint
A PUBLICIS HEALTH COMPANY



PDI
A PUBLICIS HEALTH COMPANY



Tardis Medical
A PUBLICIS HEALTH COMPANY



CustomPoint Recruiting
A PUBLICIS HEALTH COMPANY



PHfrequency
A PUBLICIS HEALTH COMPANY

Awards...



PPD EARNS AWARDS FOR REGULATORY AFFAIRS EXCELLENCE

PPD has earned two honors for excellence in regulatory affairs at The Organization for Professionals in Regulatory Affairs Awards.

PPD was also named Best CRO Provider at the World ADC Awards, which acknowledges the CRO's excellence and dedication of PPD Laboratories professionals in supporting clients' antibody-drug conjugate research to develop new anticancer therapies.

TESARO EXECS NAMED EY ENTREPRENEURS OF THE YEAR

Tesaro, an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., president and chief operating officer, have been named EY Entrepreneurs of the Year 2017 Overall National Award Winners. They were also recognized as the National Award Winners in the Life Sciences category. The award honors those who make a difference through the way they encourage entrepreneurial activity and recognizes the contribution of people who inspire others with their vision, leadership, and achievement.




WORKING MOTHER NAMES PHARMA COMPANIES AS 100 BEST COMPANIES

Astellas, Novo Nordisk, Roche Diagnostics, and Takeda have been honored as part of Working Mother's 100 Best Companies for their strong leadership in creating progressive programs for its workforce in the areas of advancement of women, flexibility, childcare, and paid parental leave.

U.S. R&D INVESTMENT GROWS

Total U.S. investment in medical and health R&D in the United States grew by 20.6% from 2013 to 2016 led by industry and the federal government, according Research!America. The medical/health industry invests more than any other sector, accounting for 67.4% of total spending in 2016. Biopharmaceutical companies contributed the largest share of funding (77.5%) in 2016, accounting for more than half (52.3%) of total U.S. R&D spending.

Prescription Drug Trends Projected to be Less Severe



Source: The Segal Group

Gilead Makes 10-Year COMMITMENT TO HIV/AIDS



New initiative aims to mobilize local communities to implement solutions for well-being, mental health, and trauma-informed care; and awareness, education, and anti-stigma campaigns.

Gilead Sciences has launched the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative, a 10-year, \$100 million commitment to support organizations working to address the HIV/AIDS epidemic in the southern United States.

Gilead is partnering with three coordinating centers to lead the corporate giving program of the initiative: Emory University Rollins School of Public Health, the University of Houston Graduate College of Social Work, and the Southern AIDS Coalition.

(c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact mwals@pharmavoic.com

Boehringer Ingelheim Makes Molecules Available TO THE SCIENTIFIC COMMUNITY

Boehringer Ingelheim has launched opnME.com, a new platform offering free and open access to selected preclinical molecules for nonclinical investigation to scientists worldwide.

Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.

The majority of molecules are offered without entering into intellectual property discussions. For selected molecules, a crowdsourcing option offers the opportunity to initiate joint research projects.

This launch is part of Boehringer Ingelheim's ongoing mission to further scientific research and medical progress through collaboration and innovation. Other initiatives include Research Beyond Borders and the Boehringer Ingelheim Venture Fund.

Top Health Industry Issues of 2018

1. Meet your new co-worker, artificial intelligence
2. Health reform isn't over; it's just more complicated
3. Medicare Advantage swells in 2018
4. Healthcare's endangered middlemen, the PBMs
5. The healthcare industry tackles the opioid crisis
6. Securing the Internet of Things
7. 2018 is the year of strategic patient experience
8. Price transparency moves to the state house
9. Social determinants come to the forefront
10. Real-world evidence is a growing challenge for pharma
11. Disaster preparation
12. Tax reform moves forward

Source: PwC Health Research Institute

PHARMAVOICE.COM

E-BOOKS:

» A New Era

Sponsored by: Healthcare Businesswomen's Association

PODCASTS:

» Whole Slide Imaging and Its Potential Role in Clinical Trials and Primary Diagnostics

Sponsored by: ACM Global Laboratories

» Building a Collaborative HCP-Patient Relationship: Insights from Health Psychology

Sponsored by: Atlantis Healthcare

» Death of the Campaign Factory: Why Advertising Agencies Must Evolve

Sponsored by: precisioneffect

WEBINARS:

» How to Avoid the 5 Patient Enrollment Mistakes That Delay Clinical Trials (OnDemand version)

Sponsored by: Acurian

» 2018 Healthcare Predictions

Sponsored by: InCrowd

WHITE PAPERS:

» Enhancing Therapeutic Alliance and Promoting Shared Decision Making

Provided by: Atlantis Healthcare

» How Digital Pathology is Revolutionizing Clinical Trials

Provided by: ACM Global Laboratories

» CX: Pharma's Search for Excellence

Provided by: eyeforpharma

OctaPharma DONATES NUWIQ

Octapharma has donated 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq, in collaboration with Project SHARE, which provides hemophilia factor replacement therapy to people in countries where these medicines are scarce or still unavailable.

PharmaVOICE
100

NEWS

ERT ACQUIRES ICARDIAC TECHNOLOGIES



Alex Zapesochny

ERT, a global data and technology company, has acquired iCardiac Technologies, a provider of centralized cardiac safety and respiratory solutions that accelerate clinical research. The acquisition enables ERT to expand its portfolio of cardiac safety solutions, specifically through the addition of iCardiac's algorithm-driven technology.

Alex Zapesochny, president and CEO of iCardiac, joins ERT's executive team to lead the company's cardiac safety business. "I look forward to continuing this tradition of helping customers navigate an increasingly complex clinical development landscape and

bring new treatments to market faster," Mr. Zapesochny says.

Mr. Zapesochny was a PharmaVOICE 100 honoree in 2016.

SYNEOS HEALTH STRENGTHENS LEADERSHIP



Michelle Keefe

Syneos Health, an integrated biopharmaceutical solutions organization combining a CRO and a CCO, has appointed Michelle Keefe president, commercial solutions, effective Dec. 1, 2017, succeeding Michael Bell. Mr. Bell continues as chairman of the board of directors.

Ms. Keefe was a PharmaVOICE Red Jacket honoree in 2016.